- Home
- PRPO vs APVO Comparison
PRPO vs APVO Comparison
Compare PRPO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- APVO
- Stock Information
- Founded
- PRPO N/A
- APVO 2016
- Country
- PRPO United States
- APVO United States
- Employees
- PRPO N/A
- APVO N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- APVO Health Care
- Exchange
- PRPO Nasdaq
- APVO Nasdaq
- Market Cap
- PRPO N/A
- APVO 4.1M
- IPO Year
- PRPO N/A
- APVO N/A
- Fundamental
- Price
- PRPO $11.79
- APVO $2.96
- Analyst Decision
- PRPO
- APVO Strong Buy
- Analyst Count
- PRPO 0
- APVO 1
- Target Price
- PRPO N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- PRPO 9.8K
- APVO 6.7M
- Earning Date
- PRPO 08-12-2025
- APVO 08-07-2025
- Dividend Yield
- PRPO N/A
- APVO N/A
- EPS Growth
- PRPO N/A
- APVO N/A
- EPS
- PRPO N/A
- APVO N/A
- Revenue
- PRPO $20,029,000.00
- APVO N/A
- Revenue This Year
- PRPO N/A
- APVO N/A
- Revenue Next Year
- PRPO N/A
- APVO N/A
- P/E Ratio
- PRPO N/A
- APVO N/A
- Revenue Growth
- PRPO 26.67
- APVO N/A
- 52 Week Low
- PRPO $3.90
- APVO $2.81
- 52 Week High
- PRPO $12.45
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- PRPO 65.45
- APVO 33.90
- Support Level
- PRPO $10.60
- APVO $2.92
- Resistance Level
- PRPO $11.70
- APVO $3.19
- Average True Range (ATR)
- PRPO 0.60
- APVO 1.05
- MACD
- PRPO -0.08
- APVO 0.24
- Stochastic Oscillator
- PRPO 79.57
- APVO 2.23
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.